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1 Background 
1.1 Drug  
Generic/Brand name/ATC code: Gefitinib/Iressa®/ L01XE02 
Developer/Company: Astra Zeneca 
Description: Gefitinib is an inhibitor of the epidermal growth factor recep-
tor (EGFR) tyrosine kinase. To predict response to this tyrosine kinase in-
hibitor (TKI), several biomarkers such as EGFR gene copy number or 
EGFR protein expression were discussed, but DNA mutational analysis is 
now the preferred method which allows identifying patients with activating 
mutations in EGFR (i.e. exon 19 deletions or exon 21 L858R point muta-
tions) [1, 2].  
Administration: 250 mg gefitinib are administered orally once daily.  
1.2 Indication  
Gefitinib is indicated as 1st-line mono-therapy for patients with EGFR muta-
tions and advanced or metastatic non-small cell lung cancer (NSCLC). 
1.3 Burden of disease 
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer- 
deaths worldwide. Its primary risk factors are first- and second-hand smoke 
exposition [1]. Men are still more often affected by NSCLC than women, 
with the majority of patients being diagnosed at an age ≥ 65 years [3]. On 
average, patients are aged 71 years at the time of diagnosis of NSCLC.  
Based on the tumour node metastasis (TNM) system which takes character-
istics like tumour size, location and invasion of the surrounding tissue, pres-
ence of metastasis in the lymph nodes or distant metastasis into account, 
four stages are distinguished. Locally advanced and metastasised NSCLC 
corresponds to TNM stage IIIB and IV, respectively [4]. 
1st-line therapy of advanced NSCLC depends on a number of factors, such as 
tumour stage, histo-pathologic subtype and performance status [1, 2]. In ad-
dition, due to the development of targeted therapies such as gefitinib, EGFR 
mutational status should also be assessed prior to therapy. Guidelines differ, 
whether routine testing for EGFR mutations is indicated regardless of the 
histo-pathologic subtype. For example, the “National Comprehensive Can-
cer Guidelines” [1] do not recommend EGFR testing for squamous cell car-
cinoma (one type of NSCLC) due to the low incidence of mutations (i.e. in 
less than 3.6% of patients) whereas UpToDate online [5] does not differenti-
ate between squamous cell carcinomas and adenocarcinomas. 
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3,600 people died of lung cancer and, about 4,100 new cases of lung cancer 
were diagnosed in Austria in 2008 [6]. As NSCLC accounts for about 85% of 
all lung cancer cases [7] of which 85% [1, 8] can be expected to present with 
advanced disease, an estimated 2,960 persons are diagnosed with advanced 
NSCLC per year. Applying estimates of an average frequency of activating 
EGFR mutations (within an unselected population about 15%) to these 
numbers would result in about 440 individuals with activating EGFR muta-
tions and thus potentially eligible for treatment with Iressa®. 
1.4 Current treatment options 
Treatment options for 1st-line therapy for patients with advanced/metastatic 
disease (TNM IIIB, IV) are  
 platinum based chemotherapy: modern regimens are mostly based on 
a platinum compound (cisplatin, carboplatin) in addition to one out 
of numerous other substances (e.g. vinorelbine, paclitaxel, docetaxel, 
gemcitabine, pemetrexed) but for none of these combinations superi-
ority has been established unequivocally. These doublets can be com-
bined with monoclonal antibodies, foremost bevacizumab, in patients 
with non-squamous NSCLC. 
 other chemotherapeutic regimens: due to the toxicity of platinum 
based regimens, other drug combinations can be used (gemcitabine + 
docetaxel/paclitaxel/vinorelbine/pemetrexed, paclitaxel + vinorel-
bine).  
 single agent chemotherapy as 1st-line treatment is generally used for 
elderly patients or for those with poor performance status.  
 radiation therapy 
 targeted therapies:  
 TKIs as mono-therapy (erlotinib (EMA’s Committee for Medicinal 
Products for Human Use adopted a positive opinion for 1st line 
therapy of NSCLC in July 2011 [9]), gefitinib) 
 monoclonal antibodies (bevacizumab) in combination with chemo-
therapy [2]. 
However, if patients are EGFR mutational status positive, EGFR-TK inhibi-
tors such as gefitinib are increasingly used as standard 1st-line therapy, 
whereas patients with either unknown EGFR status or without EGFR muta-
tion, should receive chemotherapy doublets, either alone, or in combination 
with a monoclonal antibody (e.g. bevacizumab) [5]. 
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1.5 Current regulatory status 
The EMA granted market authorization for gefitinib for the treatment of 
adult patients with locally advanced or metastatic NSCLC with activating 
mutations of EGFR TK in June 2009 [10].  
In the US, the FDA had approved gefitinib in 2003 but limited the indica-
tion in 2005 to mono-therapy for the continued treatment of patients with 
locally advanced or metastatic NSCLC after failure of both platinum-based 
and docetaxel chemotherapies who are benefiting or have benefited from ge-
fitinib [11].   
1.6 Treatment costs  
One package of Iressa®  containing 30 tablets à 250 mg costs € 2,463 per 
month [12]. In a pivotal phase III trial [13], median duration of treatment 
was 6.4 months. Assuming that treatment is administered for 6 months on 
average, total treatment costs of € 14,616.- will incur. Savings might arise by 
sparing patients considerable side-effects associated with platinum-based 
chemotherapies, leading to a reduction of in-patient treatments.   
2 Evidence 
A literature search was conducted in addition to a hand search on the 25th 
and 26th of July 2011 in the following databases: Cochrane Library, Ovid 
Medline, CRD Database and EMBASE. Search terms included were “Carci-
noma, Non-Small-Cell Lung”, “non small cell lung cancer”, “gefitinib”, “ir-
essa”, “NSCLC”, “first line”, “1st line”, “untreated”, “chemotherapy naïve”. 
After removing duplicates, 553 references were identified. Of those, only 
randomised controlled trials (RCTs) and meta-analyses presenting results 
for EGFR mutational positive patients treated with 1st-line gefitinib were in-
cluded. Overall, 7 references reporting results of 4 RCTs and 1 meta-analysis 
were included [13-19]. 
In comparison to the initial HSS report [20], final overall survival (OS) re-
sults of the IPASS trial  have become available [14], two additional studies 
were found [17, 21] and the results of the NEJ002 trial have been fully pub-
lished [19]. 
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2.1 Efficacy and safety - RCTs 
Table 1: efficacy and safety of studies enrolling patients regardless of EGFR mutational status 
Reference  Mok et al.; Fukuoka et al., IPASS trial [13, 14]  Lee et al., first-SIGNAL study, unpublished, conference presentation available [15, 
16] 
Sponsor Astra Zeneca Astra Zeneca 
Country China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, Taiwan, Thai-
land 
Korea 
Design phase III, open-label, multicentre, randomized controlled, non-inferiority trial Randomized, phase III 
Hypothesis non-inferiority NA 
Number of patients  I 609 vs C 608 I 159 vs C 150 
Treatment   
Intervention gefitinib 250mg/d, orally 
 
gefitinib 250mg/d, orally 
 
Control 200mg/m2 paclitaxel (d1), iv + carboplatin (AUC 5-6 mg per millilitre per minute, 
administered iv over a period of 15-60 minutes) once per cycle (= 3 weeks) for up to 
6 cycles 
1250mg/m2 gemcitabine on day 1 & 8 + 80mg/m2 cisplatin on day 1 every 3 weeks 
up to 9 cycles 
Inclusion criteria untreated patients, NSCLC stage IIIB or IV, non-smokers (<100 cigarettes in their 
lifetime) or light smokers (≤10 pack-years, or quit smoking ≥ 15 yrs before), ECOG 
PS 0 to 2 
untreated, never-smokers, adenocarcinoma, ECOG PS 0-2, stage IIIB or IV 
 Participants  
characteristics 
 
 
  
Median age years (range)  I 57  (24-84) vs C 57 (25-84)  
Females (%) I 78 vs C 79 I 88 vs C 89 
Non-smokers (%) I 94 vs C 94 I 100 vs C 100 
Adenocarcinoma (%) I 95 vs C 97 I 100 vs C 100 
Stage IIIB (%) I 25 vs C 24 I 10 vs C 10 
Stage IV (%) I 75 vs C 76 I 90 vs C 90 
EGFR mutations (%) I 22 vs C 21 I 49 vs C 37 
Performance Status ≤1 (%)  WHO: I 90 vs C 89  ECOG: I 91 vs C 91 
Follow-up median: 5.6 months NA 
OS  (primary outcome) 
median (months) Interim analysis: 
I 18.6 vs C 17.3  
Final analysis: 
I 18.8 vs 17.4 
I 21.3 vs C 23.3  
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HR Interim analysis: 
0.91 (95%CI 0.76 to 1.10) 
Final analysis: 
0.90 (95%CI 0.79 to 1.02; p=0.109) 
1.00 (95%CI 0.75 to 1.34, p= 0.43) 
subgroups according to EGFR 
status 
EGFR mutation positive: HR= 0.78 (95% CI 0.50 to 1.20) 
 
EGFR mutation negative: HR= 1.38 (95% CI 0.92 to 2.09) 
positive: I 30.6 months vs C 26.5 months 
HR= 0.82 (95%CI 0.35 to 1.92, p= 0.65) 
 
negative: I 18.4 months vs 23.3 months 
HR=1.2 (95%CI 0.57 to 2.52, p= 0.63) 
PFS (primary outcome)  
median (months) I 5.7 vs C 5.8  I 6.1 vs C 6.6  
HR 0.74 (95% CI 0.65 to 0.85, p<0.001) 0.813 (95%CI 0.641 to 1.031, p=0.044) 
subgroups according to EGFR 
mutational status 
positive: HR = 0.48 
(95% CI 0.36 to 0.64, p<0.001) 
negative: HR = 2.85 
(95% CI 2.05 to 3.98, p<0.001) 
positive: I 8.4 months vs C 6.7 months 
HR= 0.61 (95%CI 0.31 to 1.22, p= 0.08) 
negative : I 2.1 months vs 6.4 months 
HR=1.5 (95%CI 0.88 to 2.62, p= 0.07) 
ORR (%) I 43 vs C 32.2 
OR=1.59 (95% CI 1.25 to 2.01, p<0.001) 
 
- 
subgroups according to EGFR 
mutational status  
positive: I 71.2 vs C 47.3 (p<0.001) 
negative: I 1.1 vs C 23.5 (p=0.001) 
positive: I 84.6 vs C 37.5, OR= 9.17 (95%CI 2.11 to 39.85, p= 0.002) 
negative: I 25.9 vs C 51.9, OR= 0.33 (95%CI 0.10 to 1.02, p=0.05) 
QoL FACT-L: OR=1.34 
(95% CI 1.06 to 1.69, p=0.01) 
TOI: OR= 1.78 
(95%CI 1.4 to 2.26, p<0.001) 
 
EORTC QLQ-C30 and QLQ-LC13: more favourable outcomes for I group for global 
health status (p=0.0007), role functioning (p=0.007), social functioning 
(p=0.002) 
subgroups according to EGFR 
mutational status 
positive: FACT-L QoL improvement rate: 70.2% vs 44.5%, p<0.0001 
negative FACT-L QoL improvement rate: 14.6% vs 36.3%, p=0.0021 
 
 
Any grade AEs  I C  
Hematologic Febrile Neutropenia 
 
0.2 
 
0.2 
 
- 
Non-hematologic Rash 
Dry skin 
Diarrhoea 
Paronychia 
Anorexia 
Pruritus 
Asthenia 
Stomatitis 
Nausea 
Constipation 
Vomiting 
ILD 
66.2 
23.9 
46.6 
13.5 
21.9 
19.4 
16.8 
17.0 
16.6 
12.0 
12.9 
2.6 
22.4 
2.9 
21.7 
0 
42.6 
12.6 
44.0 
8.7 
44.3 
29.4 
33.3 
1.4 
- 
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Grade ≥3 AEs  I C  
Hematologic Leukopenia 
Anaemia 
Neutropenia 
1.5 
2.2 
3.7 
35 
10.6 
67.1 
- 
Non-hematologic Rash 
Dry skin 
Diarrhoea 
Paronychia 
Anorexia 
Pruritus 
Asthenia 
Stomatitis 
Nausea 
Constipation 
Vomiting 
3.1 
0 
3.8 
0.3 
1.5 
0.7 
0.3 
0.2 
0.3 
0 
0.2 
0.8 
0 
1.4 
0 
2.7 
0.2 
1.9 
0.2 
1.5 
0.2 
2.7 
- 
Deaths associated with AEs  3.8 2.7 - 
Notes 52% of the chemotherapy group received TKIs and 65% of the gefitinib  group were 
treated with chemotherapy after study treatment discontinuation 
post-study use of EGFR TKIs in 81% of patients in chemotherapy group                     
 
Table 2: efficacy and safety of studies enrolling only patients with EGFR mutations 
Reference  Mitsudomi et al., WJTOG3405 [17] Maemondo et al. NEJ002 [18, 19] 
Sponsor West Japan Oncology Group (WJOG) Japan Society for Promotion of Science , Japanese Foundation for the Multidisci-
plinary Treatment of Cancer, Tokyo Oncology Group 
Country Japan Japan 
Design multicentre, randomised, open-label, phase III multicentre, randomised, phase III 
Hypothesis superiority superiority 
Number of patients  I 86 vs C 86 I 114 vs C 114 
Treatment   
Intervention gefitinib 250mg/d, orally 
 
gefitinib 250mg/d, orally 
Control 60mg/m2 docetaxel, iv + 80mg/m2 cisplatin, iv; administered every 21 days for three 
to six cycles 
200mg/m2 paclitaxel, iv + 
carboplatin (AUC 6), iv; both administered at the first day of a 3-week cycle for at 
least 3 cycles 
Inclusion criteria NSCLC stage IIIB or IV, WHO PS 0 or 1, activating EGFR mutations, postoperative re-
currence, treated with adjuvant therapy other than cisplatin plus docetaxel, when the 
interval between the end of adjuvant chemotherapy and registration > 6 months for 
platinum-doublet therapy and > 1 month for oral tegafur plus uracil therapy, ≤75 
years 
 
untreated, advanced non–small-cell lung cancer 
harbouring sensitive EGFR mutations, ≤75 years 
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 Participants  
characteristics 
  
Median age years (range)  I 64 (34–74) vs C 64 (41–75) I 64 (43-75) vs C 63 (35-75) 
Females (%) I 69 vs C 70 I 63 vs C 64 
Non-smokers (%) I 71 vs C 66 I 66 vs C 58 
Adenocarcinoma (%) I 97 vs C 98 I 90 vs C 97 
Stage IIIB (%) I 10 pts vs C 9 pts I 13 vs C 18 
Stage IV (%) I 41 pts vs C 41 pts I 77 vs C 74 
EGFRmutations (%) I 100 vs C 100 I 100 vs C 100 
Performance Status ≤1 (%) WHO: I 86 vs C 86  ECOG: I 99 vs C 98  
Follow-up median: 81 days median: 527 days 
OS   
Median (months) I 30.9 (95%CI 24.1+) vs C 
not reached (95% CI 15.0+) 
I 30.5 vs C 23.6 (p=0.31) 
HR 1.638 (95% CI 0.75 – 3.58), p=0.21 - 
PFS (primary outcome) (primary outcome) 
Median (months) I 9.2 vs C 6.3 Interim analysis: I 10.4 vs C 5.5 
Final analysis: I 10.8 vs C 5.4 
HR 0.489 (95% CI 0.336–0.710; p<0.0001) Interim analysis: 0.36 (95% CI 0.25 - 0.51; p<0.001) 
Final analysis: 0.30;(95% CI 0.22 - 0.41; p<0.001) 
ORR (%) I 62.1 (36 of 58 patients) vs C  32.2 (19 of 59 patients), p<0.0001 I 73.7 vs C 30.7; p<0.001 
QoL NA Care notebook questionnaire: time to deterioration of Physical Well-Being: HR = 
0.28 (p<0.001) 
Time to deterioration of Life Well-Being: HR=0.88 (p=0.55) 
Any grade AEs  I C  I C 
Hematologic Leucopenia 
Anaemia 
Neutropenia 
Thrombocytopenia 
15 
38 
8 
14 
93 
89 
92 
33 
Anaemia 
Neutropenia 
Thrombocytopenia 
18.4 
6.1 
7 
64.6 
77 
28.3 
Non-hematologic Rash 
Liver enzymes  
Dry skin 
Diarrhoea 
Fatigue 
Paronychia 
Stomatitis 
Nausea 
Constipation 
Alopecia 
ILD 
 
 
85 
70 
54 
54 
39 
32 
22 
21 
16 
9 
2 
8 
40 
3 
40 
83 
1 
15 
94 
44 
76 
0 
ILD 
Rash 
Liver enzymes  
Dry skin 
Diarrhoea 
Fatigue 
Appetite loss 
Neuropathy 
Arthralgia 
Pneumonitis 
5.3 
71.7 
55.3 
- 
34.2 
10.5 
14.9 
0.9 
3.5 
5.3 
0 
22.1 
32.7 
- 
6.2 
27.4 
56.6 
54.9 
47.8 
0 
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Grade ≥3 AEs  I C  I C 
Hematologic Leukopenia 
Anaemia 
Neutropenia 
Thrombocytopenia 
0 
0 
0 
0 
49 
17 
84 
0 
Anaemia 
Neutropenia 
Thrombocytopenia 
0 
0.9 
0 
5.3 
65.5 
3.5 
Non-hematologic Rash 
Liver enzymes  
Dry skin 
Diarrhoea 
Fatigue 
Paronychia 
Stomatitis 
Nausea 
Constipation 
Alopecia 
2 
28 
0 
1 
2 
1 
0 
1 
0 
0 
0 
2 
0 
0 
2 
0 
0 
3 
0 
0 
Overall grade ≥3 
Rash 
Liver enzymes  
Dry skin 
Diarrhoea 
Fatigue 
Appetite loss 
Neuropathy 
Arthralgia 
Pneumonitis 
41.2 
5.3 
26.3 
- 
0.9 
2.6 
5.3 
0 
0.9 
2.3 
71.7 
2.7 
0.9 
- 
0 
0.9 
6.2 
6.2 
7.1 
0 
Deaths associated with AEs  1.1 0  NR 
Notes interim analysis was originally planned to analyse progression-free survival, but this 
analysis was not done. Instead, the steering committee held on June 13, 2009, pro-
posed the amendment of the sample size and the final analyses be done using avail-
able data. immature data for OS but follow-up on-going 
The pre-planned interim analysis was performed 4 months after the 200th patient 
was enrolled (May 2009); 
and the independent data and safety monitoring committee recommended termi-
nation of the study. Therefore, the study was stopped at the end of May 2009;  
after study treatment discontinuation, 95% of the chemotherapy group conse-
quently received 2nd-line gefitinib and 68% of the gefitinib group received plati-
num-based doublets 
 
Abbreviations: AE= adverse event, EORTC QLQ = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, TOI= trial outcome index, FACT-L = Functional 
Assessment of Cancer Therapy – Lung, ILD – Interstitial-lung-disease, WHO PS – World Health Organisation performance status, ECOG PS – Eastern Cooperative Oncology Group perform-
ance status, iv – intravenously; NCI-CTC – National Cancer Institute Common Terminology Criteria, version 3.0 (http://www.eortc.be/services/doc/ctc/ctcaev3.pdf), OS = overall survival, PFS 
= progression-free survival, ORR = overall response rate, QoL =quality-of-life, CI = confidence interval, HR = hazard ratio 
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Overall four trials report results for 1st-line mono-therapy with gefitinib for 
patients with EGFR mutations. Of those, one is only available as abstract 
[15, 16], two trials included only patients with EGFR mutations [17, 19], 
whereas the other two present results for EGFR mutational positive sub-
groups [13, 15]. Nonetheless, all trials enrolled patients which are likely to 
have EGFR mutations (i.e. women, never-smokers, adenocarcinomas).  
Results of the IPASS trial, a non-inferiority trial, were published twice: at 
first, PFS and interim results for OS were reported [13] and, more recently, 
final results of OS [14]. Another phase III trial by Maemondo et al. [19] was 
stopped after a pre-planned interim analysis had demonstrated superiority 
of gefitinib. In a 3rd trial, the WJTOG3405 trial [17], a sample size of 200 pa-
tients was initially calculated to demonstrate a HR of 0.56. Due to the fact 
that results of the IPASS as well as NEJ002 trial had been published while 
the study was on-going, further patient accrual was “considered to be futile 
and potentially unethical” [17]. The sample size was thus amended and the 
final analysis was performed based on the data available. However, follow-
up data for safety and OS will be collected for an additional 1.5 years.  
PFS was the primary outcome in three trials [13, 17, 19] and showed consis-
tent results for patients with EGFR mutations, favouring the gefitinib 
groups. Only the first-SIGNAL study deviated, because PFS was not im-
proved in the subgroup with EGFR mutations, but this group was, with only 
42 patients, very small. More favourable results were also found for ORR, 
even though it should be mentioned that assessment of PFS and tumour re-
sponse was blinded in only one of the trials [19], a fact which might have 
impacted on these results.  
For QoL, which was assessed in three trials [13, 15, 18], better results for pa-
tients treated with the TKI, again more pronounced in EGFR+ patients, 
were found.  
In contrast, OS was not prolonged for patients treated with gefitinib in any 
of the trials, either for the overall populations or for patients with EGFR 
mutations. Especially the final OS results of the IPASS trial, the largest 
study, had been awaited with great interest but failed to demonstrate im-
proved outcomes for patients treated with gefitinib. But these findings are 
likely to be influenced by subsequent lines of therapies, as, for example, 52% 
of the chemotherapy group received TKIs and 65% of the gefitinib group 
were treated with chemotherapy in the IPASS trial.  
The most common AEs of any grade in patients treated with gefitinib were 
rash (I 85% vs C 8%) and diarrhoea (I 54% vs C 40%), whereas administra-
tion of chemotherapeutic regimens was more often associated with haemato-
logical AEs (e.g. leucopenia I 15% vs C 93%). Similar outcomes were also 
observed for AEs ≥3. Even though overall frequencies were reported in only 
one of the trials [19] (I 41% vs C 72%), individual AEs of higher grades also 
occurred more often in patients treated with chemotherapeutics than in 
those treated with gefitinib. Nonetheless, a maximum of 5% of patients 
treated with gefitinib developed interstitial lung disease, a sometimes fatal 
AE associated with gefitinib and more treatment-related deaths were seen in 
the TKI group overall (I 3.8% vs C 2.7%).  
 
4 trials included  
2 included only patients 
with EGFR mutations, 
2 reported results for 
EGFR mutational status 
positive subgroups 
results for PFS 
consistent , favouring 
the gefitinib group 
also better QoL 
outcomes  
OS was not prolonged in 
any of the trials, not 
even in patients with 
EGFR mutations  
but difficult to interpret 
this finding, because of 
subsequent lines of 
therapy 
most common AEs of 
gefitinib were rash and 
diarrhoea, whereas 
haematological AEs 
were more frequent in 
chemotherapeutics 
group 
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2.2 Efficacy and safety - further studies 
Ku et al. [21] conducted a meta-analysis of all trials mentioned above, thus 
comprising nearly 2,000 patients out of which 650 patients had EGFR muta-
tions. In those patients, the combined HR for PFS was 0.45 (95%CI 0.38 – 
0.55; p<10-16), but like the individual studies, no significant difference was 
found for OS. Amongst patients with EGFR mutations the overall estimated 
odds ratio of ORR was 4.04 (95%CI 2.90-5.61, p<10-15). 
3 Commentary  
Since the EMA granted market authorization for gefitinib in June 2009, sev-
eral studies focusing on patients with EGFR mutations have been published 
besides the IPASS trial. In addition, mature data for OS of the IPASS trial 
have also become available. All trials were conducted in an Asian popula-
tion, a fact that prompted the EMA already at licensing to require a post-
marketing prospective trial within a Caucasian population with confirmed 
EGFR mutations [22] (estimated study completion date is August 2012 
[23]).  
Since its licensing, gefitinib has been increasingly used as standard of care 
for 1st-line therapy of patients who have tested positive for EGFR mutations, 
not only because of prolongation of PFS but also because of a more favour-
able toxicity profile than standard platinum-based chemotherapy. The ease 
of oral application also offers an advantage to patients in comparison to che-
motherapy. In addition, even though the median duration of gefitinib ther-
apy was about 6 months in the pivotal phase III study, Iressa® is potentially 
a long-term therapy, because it can be administered as long as disease does 
not progress and toxicity remains tolerable, whereas chemotherapies are 
administered for a maximum of 6 cycles. Consequently, gefitinib therapy af-
ter EGFR testing has been incorporated into several treatment guidelines [1, 
2, 24].  
In contrast to consistent results for improved PFS and QoL in EGFR muta-
tional status positive patients across all trials, no differences were found for 
OS; a finding which was confirmed in a meta-analysis [21]. However, this re-
sult is difficult to interpret, because subsequent lines of therapies might 
have influenced these outcomes as, for example, up to 81% of patients ini-
tially treated with chemotherapy, received TKI therapy after study treat-
ment was discontinued and vice-versa. Also, only one trial explicitly men-
tioned that assessment of PFS was verified by central reviewers blinded to 
study treatment. As PFS is prone to assessment bias, especially in open-label 
trials, results for PFS might have been biased [25].  
all trials conducted in 
Asia, no results for 
Caucasian population 
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Even though clinical factors (adenocarcinoma, women, non-smokers,     
Asian ethnicity) are also useful for predicting response to EGFR TKIs [26, 
27], the provision of routine EGFR mutation testing supported by a quality 
assurance programme in Austria is challenging.  This is important, because 
of the consequences associated with either false-positive test results (i.e. de-
nial of access to chemotherapy) or false-negative test results (i.e. denial of 
access to gefitinib) [28]. Moreover, mutational status might differ depending 
on where the tissue has been derived from (i.e. primary tumour vs metastatic 
lesions) [26] and to retrieve enough tumour material from biopsies is also of-
ten difficult. Related to that are issues concerning the identification and de-
tection of further biomarkers (e.g. K-ras mutations, EML4-ALK mutations) 
which allow a more precise definition of patient groups which are either 
most likely to benefit or which are, or have become resistant to TKIs [1, 26]. 
Disease progression due to acquired resistance to TKI occurs eventually in 
all patients treated with gefitinib, leading to the development of new thera-
peutic approaches using agents which simultaneously inhibit EGFR and 
HER2 receptors [29].  
In addition, EMA’s Committee for Medicinal Products for Human Use has 
recently adopted a positive opinion to license erlotinib as 1st-line therapy for 
NSCLC patients with activating mutations of EGFR [30]. Since the costs of 
erlotinib are similar to those of gefitinib [12], a thorough comparison of effi-
cacy and safety of these two drugs is of great interest. Some initial evidence 
from a retrospective study which included 154 Asian patients indicates that 
therapy with gefitinib might be associated with fewer adverse events than er-
lotinib therapy [31]. 
Concerning costs, the English “National Institute for Health and Clinical 
Excellence” evaluated gefitinib and recommended it for the 1st-line treat-
ment of NSCLC, given that the drug will be provided under the patient ac-
cess scheme at a fixed price [32]. This scheme determines that the costs per 
patients are fixed at £12,200 (≈ € 13,600) per patient. If patients are treated 
less than 3 months with gefitinib, no costs will occur at all. Of note, the costs 
for one package Iressa® in England are the same like in Austria.  
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